Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Slides:

Advertisements

Similar presentations

Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin Featured Article: Beverley Balkau, Philip D. Home, Maya Vincent,

Advertisements

Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

Key publication slides

Neal B, et al. Diabetes Care 2015;38:403–411

Canagliflozin: Real World Experience

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Pramlintide Synthetic analog of the β-cell hormone amylin

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

Depicted are patient and disease factors used to determine optimal A1C targets. Depicted are patient and disease factors used to determine optimal A1C.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.

Guidelines for Initiation of Therapy

Change in HbA1c and weight compared with baseline variables for the liraglutide group and the placebo group. Change in HbA1c and weight compared with baseline.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Pramlintide Therapy Part 1of 2

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Deletion of neuronal insulin receptor signaling reduces TG secretion, while the targeted knockout of insulin receptors restricted to the periphery increases.

Consequences of diabetes-related stigma.

Sagittal view of hypothalamus showing a significant reduction in CBF 15 and 30 min after application of intranasal insulin compared with placebo in the.

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Change in markers of glycometabolism and cardiovascular risk profile.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Distribution of responses to the knowledge questions.

Comparative monthly and annual cost savings with RHI administered with V-Go. Comparative monthly and annual cost savings with RHI administered with V-Go.

Flow chart of patients who met inclusion/exclusion criteria in the identified study population.1 Excluded because they were living in nursing facility.

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

This pooled data from 11 prospective cohort studies with 650,386 white adults found a significant correlation in all-cause mortality when waist circumference.

Insulin sensitivity in athletes and sedentary normal-weight and obese, young, and old individuals. Insulin sensitivity in athletes and sedentary normal-weight.

Categorical A1c distribution within BMI categories, n=414 266 patients with T2D and available A1c data. % values represent percentage of subjects within.

(A) Hemoglobin A1c (HbA1c) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (B) Urinary albumin to creatinine.

Total plasma BCAA (A) and C3 and C5 acylcarnitine (AC) (B) concentrations in the basal state and during insulin infusion in obese subjects before and after.

Ca2+ infusion rates during all three protocol versions.

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Arterial and hepatic sinusoidal plasma insulin levels in conscious dogs during the basal (−40 to 0 min) and experimental (0–240 min) periods treated with.

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control patients and.

Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).

Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effect of empagliflozin on efficacy parameters at week 18.

ORs of receiving metformin for outcome measures, including age, number of comorbidities, provider age, A1C level, history of CHF, and use of medications,

Glycemic control and body weight over 52 weeks.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Cytokine changes in LPS-induced TNFα and spontaneous IL-6 production in whole-blood cultures. Cytokine changes in LPS-induced TNFα and spontaneous IL-6.

Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

A1C at baseline and each maintenance month by treatment in the GEMINI trial, including the modified intention-to-treat population. A1C at baseline and.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Postprandial glucose, insulin and glucagon-like peptide-1 (GLP-1) levels following carbohydrate-first (CF), carbohydrate-last (CL) and sandwich (S) meal.

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.

Effects of PCSK7 rs genotype and CHO diets on changes and reversion in fasting insulin levels and HOMA-IR during the 2-year intervention in white.

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

Survival RR enhancement according to the specific protocol in treated mice. Survival RR enhancement according to the specific protocol in treated mice.

Adjusted ORs of increasing severity of heartburn at follow-up in reference to baseline from model adjusted for BMI category, CVD history, BDI score >11,

(A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects. (A) Twenty-four-hour plasma profiles of insulin and amylin in healthy subjects.

Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.

Change in first-phase insulin response (A) and pancreas triglyceride content (B) in responders and nonresponders at baseline (hatched bars), after VLCD.

Presentation transcript:

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes treated with placebo + insulin or pramlintide + insulin. Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes treated with placebo + insulin or pramlintide + insulin. From ref. 52 and ref. 53. Statistical significance is denoted by * (P < 0.05) and ** (P < 0.001). In both types of diabetes, addition of pramlintide to existing insulin therapy led to significant and sustained reductions in both A1C and body weight. John B. Buse et al. Clin Diabetes 2002;20:137-144 ©2002 by American Diabetes Association